New collaborative research center in cancer research

- EN - DE
In TRR 387 UbiQancer, the researchers want to gain new insights into the functio
In TRR 387 UbiQancer, the researchers want to gain new insights into the function of the ubiquitin system in certain types of cancer and hope to generate new drugs based on these findings.


DFG approves Transregio UbiQancer

The German Research Foundation (DFG) will fund a new Collaborative Research Center led by the Technical University of Munich (TUM): Transregio 387 will focus on how the ubiquitin system can be used for cancer therapies. Funding has also been extended for another Transregio with TUM participation.

The DFG’s Collaborative Research Centers are one of the most important research funding programs in Germany. They support ambitious, interdisciplinary and long-term research projects. These centers are initially approved for four years, but can be funded for up to twelve years in total. ...
account creation

TO READ THIS ARTICLE, CREATE YOUR ACCOUNT

And extend your reading, free of charge and with no commitment.

Register


Login


Subscribe